A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-8931 When Administered to Subjects With Mild and Moderate Hepatic Insufficiency
Phase of Trial: Phase I
Latest Information Update: 16 May 2017
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 11 May 2017 Status changed from recruiting to completed.
- 28 Apr 2017 Planned End Date changed from 1 Apr 2017 to 19 Jul 2017.
- 28 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 10 Jul 2017.